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Abstract. The aim of the present study is to compare the 
safety, efficacy and cost effectiveness of anesthetic regimens 
by compound, using etomidate and propofol in elderly patients 
undergoing gastroscopy. A total of 200 volunteers (65‑79 years 
of age) scheduled for gastroscopy under anesthesia were 
randomly divided into the following groups: P, propofol 
(1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol 
(0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg); 
and E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol 
(0.75‑1 mg/kg). Vital signs and bispectral index were moni-
tored at different time points. Complications, induction and 
examination time, anesthesia duration, and recovery and 
discharge time were recorded. At the end of the procedure, 
the satisfaction of patients, endoscopists and the anesthetist 
were evaluated. The recovery (6.1±1.2 h) and discharge times 
(24.8±2.8 h) in group E were significantly longer compared 
with groups P, P+E and E+P (P<0.05). The occurrence of 
injection pain in group P+E was significantly higher compared 
with the other three groups (P<0.05). In addition, the incidence 
of myoclonus and post‑operative nausea and vomiting were 
significantly higher in group P+E compared with the other 
three groups (P<0.05). There was no statistical difference 
among the four groups with regards to the patients' immediate, 
post‑procedure satisfaction (P>0.05). Furthermore, there was 
no difference in the satisfaction of anesthesia, as evaluated 
by the anesthetist and endoscopist, among the four groups 
(P>0.05). The present study demonstrates that anesthesia for 
gastroscopy in elderly patients can be safely and effectively 
accomplished using a drug regimen that combines propofol 
with etomidate. The combined use of propofol and etomidate 
has unique characteristics which improve hemodynamic 
stability, cause minimal respiratory depression and less side 
effects, provide rapid return to full activity and result in high 
levels of satisfaction.
Introduction
Gastroscopy is a well‑established, highly effective diagnostic 
and therapeutic procedure. The frequency of this procedure 
in the elderly is increasing rapidly as the general population 
ages (1,2). Although it is a non‑traumatic invasive proce-
dure, it often causes significant discomfort in the majority 
of patients. With the collaboration of the anesthesia and 
digestive system departments, gastroscopy under anesthesia 
minimizes the risk of physical injury occurring during 
examination, and provides the endoscopist with a suitable 
environment for a thorough examination. This has been 
reported to be safe in high risk patients, including elderly, 
frail and seriously ill patients (3,4). Despite the benefits of 
using anesthesia for gastroscopy, it has significant draw-
backs. Anesthesia can delay patient recovery and discharge 
time, and increases the risk of cardiopulmonary complica-
tions, which are understood to account for ~50% mortality 
and ~60% morbidity associated with upper gastrointestinal 
endoscopy (5,6). This risk is increased in elderly patients or 
those with cardiovascular diseases and upper gastrointestinal 
bleeding (7). Arterial hypoxemia, arrhythmias and myocar-
dial ischemia have been reported following gastroscopy with 
anesthesia (7).
Anesthesia strategies for gastroscopy have been explored 
for decades. There are numerous reports on the safety profile 
of propofol used for anesthesia during gastrointestinal 
endoscopy (8‑10). Propofol is currently the most frequently 
used intravenous anesthetic, due to its rapid recovery profile, 
and is widely used in outpatient surgeries and examina-
tions (4,10). The most prominent undesirable effect of propofol 
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is its marked depression on cardiovascular and respiratory 
parameters, particularly in elderly patients (9‑10). The 
distinct pharmacological characteristics of etomidate include 
improved hemodynamic stability and minimal respiratory 
depression (11). This results in a wider margin of safety for 
patients with significant risk factors, including patients with 
valvular heart disease and myocardial ischemia, and elderly 
patients. However, due to side effects, including myoclonus 
and post‑operative nausea and vomiting (PONV), etomidate is 
rarely used in patients undergoing gastroscopy.
The aim of the present prospective study is to determine 
the safety, efficacy, cost effectiveness, side effect profile and 
recovery time of a combination of propofol and etomidate, 
compared with propofol and etomidate alone, as anesthetic 
regimens for gastroscopy.
Materials and methods
Patients and study design. The current study is a double‑blinded, 
randomized, parallel‑group study, performed in accordance 
with the International Conference on Harmonization Good 
Clinical Practice guidelines (8). The study was approved by the 
Ethics Committee of Renmin Hospital of Wuhan University 
(Wuhan, China), and informed consent was obtained from 
all patients. A total of 200 healthy, American Society of 
Anesthesiologists grade I‑II patients, consisting of 97 males 
and 103 females, aged between 65 and 79 years, who were 
scheduled for gastroscopy with anesthesia, were included in the 
study. Patients had normal serum chemistry, and normal liver 
and renal function test results. No patients were experiencing 
cardiac or respiratory disease. Exclusion criteria included the 
following: Severe dysfunction of heart; lung, liver, kidney and 
adrenal insufficiency; sleep apnea syndrome; gastric retention; 
history of an allergic reaction to the study drugs; history of 
previous experience with endoscopy; patients receiving anal-
gesics, such as nonsteroidal anti‑inflammatory drugs; patients 
administered α‑methyldopa, clonidine or a β‑blocker; patients 
with psychiatric, neurological or neuromuscular disorders; or 
patients who had used drugs, drank alcohol or smoked tobacco 
two weeks prior to the study. Demographic data obtained 
included age, weight, gender and primary diagnosis. Propofol 
and etomidate doses, administered by bolus and continuous 
infusion, were recorded.
Medicine preparation, anesthesia monitoring and gastroscopy 
procedure. Drugs used in the study included 200 mg/20 ml 
propofol (AstraZeneca, London, UK), 20 mg/10 ml etomi-
date (Nhwa Pharmaceutical Group, Jiangsu, China) and 
100 mg/2 ml fentanyl (Yichang Humanwell Pharmaceutical 
Co., Ltd., Yichang, China). Etomidate and propofol were diluted 
to 20 ml prior to administration. All dugs were prepared by an 
anesthesiologist who was blinded to the study. An investigator, 
who was blinded to group assignment, assessed and recorded 
all observed parameters.
In accordance with hospital policies regarding procedural 
anesthesia, fasting status was confirmed, and a 20‑gauge 
peripheral IV catheter was placed in the right forearm 
without subcutaneous local anesthesia following the arrival 
of patients to the Digestive Endoscopy Center of Renmin 
Hospital of Wuhan University. Lactated Ringer's solution 
(Baxter International Inc., Deerfield, IL, USA) was infused, 
and routine monitoring consisting of a 5‑lead electrocardi-
ography (ECG), non‑invasive blood pressure, pulse oxygen 
saturation (SpO2) and bispectral index (BIS; Monitor Model 
A‑2000; Aspect Medical Systems, Inc., Norwood, MA, USA). 
The mean of the final 3 vital signs obtained prior to the injec-
tion of anesthetics was recorded as the baseline in all patients. 
After lying on the examination table in the left lateral posi-
tion, each patient was provided oxygen (5 l/min) via a face 
mask and instructed to take deep breathes to increase their 
oxygen reserves.
All patients received intravenous (i.v.) 1 µg/kg fentanyl 
at 5‑10 sec prior to gastroscopy. Prior to endoscopy, 
patients were randomized to one of four groups using a 
computer‑generated random numbers table, which allocated 
50 patients to each group. Patients in the propofol group (P) 
received i.v. propofol at an induction dose of 1.5‑2.0 mg.
kg-1 over a 1 min period using a computer controlled infu-
sion pump (Syringe Infusion Pump Model compact; B. 
Braun Melsungen AG, Melsungen, Germany), followed by a 
maintenance infusion of 4 mg.kg-1.h-1 during the gastroscopy 
procedure. Patients in the etomidate group (E) received i.v. 
etomidate at an induction dose of 0.15‑0.2 mg/kg over 1 min 
using the same infusion pump, followed by a maintenance 
infusion of 0.4 µg.kg-1.h-1 during the gastroscopy procedure. 
Patients in the propofol and etomidate group (P+E) received 
propofol (0.75‑1 mg/kg) over a 30 sec period and subse-
quently etomidate (0.075‑0.1 mg/kg) over a 30 sec period 
using the same infusion pump, followed by a maintenance 
infusion of 2 mg.kg-1.h-1 propofol and 0.2 µg.kg-1.h-1 etomi-
date simultaneously during the gastroscopy procedure via 
a three‑way joint. Patients in the etomidate and propofol 
group (E+P) received etomidate (0.075‑0.01 mg/kg) over 
a 30‑sec period and subsequently propofol (0.75‑1 mg/kg) 
over a 30 sec period via the same infusion pump, followed 
by a maintenance infusion of 2 mg.kg-1.h-1 propofol and 
0.2 µg.kg-1.h-1 etomidate during the gastroscopy procedure 
via a three‑way joint.
Gastroscopy was performed when eyelash reflexes disap-
peared. The gastroscopy was performed with patients in a 
left lateral position, using a side‑viewing video duodenoscope 
(Olympus Optical Co., Ltd., Tokyo, Japan). An anesthetist was 
in attendance during all procedures. Spontaneous respiration 
was maintained during the course of gastroscopy.
Observed parameters. A 5‑lead ECG was performed 
throughout the gastroscopy. In addition, reductions in SpO2, 
changes in heart rate (HR) and blood pressure (BP), ST 
segment deviations, arrhythmias and conduction defects were 
recorded throughout the procedure. Vital signs were recorded 
at T0 (baseline, prior to induction of anesthesia), T1 (2 min 
after induction of anesthesia), T2 (4 min after induction of 
anesthesia), T3 (6 min after induction of anesthesia), T4 (8 min 
after induction of anesthesia), T5 (10 min after induction of 
anesthesia), T6 (15 min after induction of anesthesia) and T7 
(20 min after induction of anesthesia).
Patients were assessed at the following time points 
for various complications: i) Start of anesthesia (first 
drug bolus); ii) start of examination (gastroscopy place-
ment); iii) completion of the examination (removal of the 
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gastroscopy); iv) 'induction time' (start of anesthesia to start 
of examination); v) 'inspection time' (gastroscopy insertion to 
gastroscopy removal); vi) 'recovery time' (the time between 
the gastroscopy removal and the start of the final psycho-
metric assessment); and vii) 'discharge time' (the time between 
gastroscopy removal and departure from the endoscopy unit). 
The criteria for discharge from the endoscopy unit were as 
follows: Fully awake with stable hemodynamics; no evidence 
of respiratory depression; no nausea or vomiting; and ability 
to drink water safely.
Rate pressure product (RPP) and pressure‑rate quotient 
(PRQ) (12), which are two indices that reflect myocardial 
oxygen consumption, were calculated following the examina-
tion as follows: RPP = systolic blood pressure (SBP) x heart 
rate (HR) / 1,000; PRQ = mean arterial pressure / HR.
Adverse events, the use of ventilator support, including 
support of the oral or nasopharyngeal airways, and the admin-
istration of pressors and chronotropic agents were recorded. 
Bradycardia was defined as a heart rate <50 beats per minute 
(bpm). Hypotension was defined as a systolic pressure <70% 
baseline or <80 mmHg. Side effects, including PONV, swal-
lowing, body movement (limb locomotor activity with no 
influence on gastroscopy), serious body movements (resulting 
in suspension of the examination), apnea (interval time of 
respiration, >30 sec), hypoxemia (SpO2,<90%), myoclonus 
(involuntary and brief twitching of a group of muscles) and 
injection pain, were recorded.
At the end of the procedure, the satisfaction of the anes-
thetist and gastroenterologist were evaluated according to the 
visual analogue scale (13) (VAS scores; 0 = no satisfaction 
and 10 = most satisfaction). A questionnaire, which inquired 
about i) overall satisfaction with the anesthesia, ii) difficulty of 
anesthesia, iii) patient cooperation, and iv) overall satisfaction 
with the gastroscopy procedure, was used.
Prior to discharge, patient satisfaction was evaluated by 
completing an anonymous and confidential Patient Satisfaction 
Questionnaire, modified from Sipe (14), to evaluate the endos-
copy experience.
Safety equipment. Vital signs were monitored for 2 h after the 
completion of the examination. The incidence of the following 
cardiorespiratory events were recorded: Bradycardia; respi-
ratory depression (RR; <9 breaths/min); apnea; hypertension 
(BP >30% baseline); and hypotension (BP <30% baseline). 
Intervention, including the administration of fluid, pressors, 
or the use of an anticholinergic agents, was applied for any 
adverse events. Mask‑assisted ventilation was performed if 
SpO2 <90% remained for 30 sec. Additionally, any events 
resulting in mortality, permanent impairment, hospitaliza-
tion and/or medical or surgical intervention were recorded.
Statistical analysis. Data are presented as the mean ± stan-
dard deviation, and medians. GraphPad Prism version 5.0 
(GraphPad Software, Inc., San Diego, CA, USA) was used 
to analyze the results. One‑way analysis of variance was 
performed to examine differences among the four groups with 
respect to parametric variables, followed by Tukey's post hoc 
test. Incidences of complications were analyzed using the χ2 or 
Fisher's exact test. P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Combined use of propofol and etomidate reduces recovery 
and discharge times, as compared with etomidate alone. 
A total of 253 patients were assessed for study eligibility; 
35 patients did not meet the inclusion criteria, 15 patients 
declined to participate and 3 patients were excluded for other 
reasons (Fig. 1). In total, 200 patients were included in the 
study (97 males and 103 females; age range, 65‑82 years). The 
four groups had similar demographic data (P>0.05; Table I) 
and BIS (P>0.05; Table I). The induction time, inspection 
time and anesthesia duration were not different between the 
four groups (P>0.05; Fig. 2). The recovery (6.1±1.2 h) and 
discharge times (24.8±2.8 h) in group E were longer compared 
with group P (4.8±0.9 h and 22.7±2.8 h, respectively), group 
P+E (5.2±0.9 h and 23.6±1.4 h, respectively) and group E+P 
(5.3±0.8 h and 23.5±1.8 h, respectively) (P<0.05; Fig. 2). No 
gastroscopy procedure was terminated because of inadequate 
patient anesthesia.
Etomidate improves hemodynamic stability, as compared 
with propofol. A decrease in BP >30% from the baseline 
occurred in 62 patients across all groups (Table II). There was 
a decrease in SBP from the baseline in all patients at T1, and 
there was a significant difference in the incidence of hypoten-
sion in group P, as compared with the other three groups (88%; 
P<0.05; Fig. 3). In addition, there were statistically significant 
differences in SBP in group P at T1, as compared with the 
other three groups (P<0.05; Fig. 3), and there were significant 
differences in SBP at T0 compared with T1, T2, T3, T4, T5 and 
T6 in group P (P<0.05; Fig. 3). Furthermore, there was a signif-
icant difference in SBP at T0 compared with T1, T2, T3, T4 
and T5 in groups E, P+E and E+P (P<0.05; Fig. 3). Moreover, 
in groups E, P+E and E+P, there was a significant difference in 
SBP at T1 (132.08±6.56, 129.56±6.58 and 131.20±5.93 mmHg, 
respectively) compared with T6 (151.28±5.73, 150.72±5.79 
and 152.16±6.65 mmHg, respectively) and T7 (157.44±5.36, 
154.36±8.04 and 158.68±5.71 mmHg, respectively) (P<0.05; 
Fig. 3). The results for the other three groups showed improved 
hemodynamic stability compared with group P (P<0.05, 
Fig. 3). There were no significant differences in the mean and 
maximum HR during gastroscopy in different groups (P>0.05, 
Fig. 3). It has been suggested that RPP ≥12 indicates myocar-
dial ischemia (12), and that RPP ≥20 is a threshold for angina 
pectoris; PRQ <1.0 is considered to be an accurate measure of 
myocardial ischemia. In the present study, 1 patient had a very 
high RPP (>20), and 2 patients had PRQ <1.0, in group P.
Combined use of propofol and etomidate causes minimal 
respiratory depression and few side effects. The incidences 
of complications resulting from gastroscopy are presented 
in Table II. No serious complication occurred during the 
study. Transient hypoxia (SpO2, <90% for >30 sec) requiring 
supplemental oxygen by mask‑assisted ventilation occurred in 
7 patients across all groups (Table II). All episodes of hypoten-
sion and bradycardia were transient, and the administration of 
a pharmacologic agent or other therapeutic intervention was 
not required to treat any of the patients. No perforations or 
mortality occurred, and following the procedure, no patient 
required assisted ventilation or was admitted to hospital.
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The occurrence of apnea during and following gastroscopy 
was 17% (34); 2% of these patients had SpO2 <90%, and 2.5% 
of the patients reported accessing mask‑assisted ventilation 
in the endoscopy unit. The occurrence of SpO2 <95% (24%), 
SpO2 <90% (8%), apnea (42%) and mask‑assisted ventilation 
(8%) in group P were significant higher compared with groups 
E (4, 0, 14 and 2%, respectively), P+E (6, 0, 6 and 2%, 
respectively) and E+P (6, 0, 6 and 2%, respectively) (P<0.05; 
Table II). There were no significant differences in the occur-
rence of SpO2 <95%, SpO2 <90%, apnea, and mask-assisted 
Table I. Patient demographics.
 Group
 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Parameter P E P+E E+P
Median age (range), years 68.4 (65‑78) 69.7 (65‑80) 72.3 (65‑79) 71.8 (65‑82)
Gender, male/female 24/26 25/25 24/26 24/26
Median weight (range), kg 60.7 (50‑84) 62.4 (52‑82) 62.6 (47‑85) 61.8 (49‑84)
There are no significant difference between the treatment groups (P>0.05). P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, 
propofol (0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).
 
Figure 1. Study profile. Flow diagram of the phases of the randomized trial.
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ventilation when comparing groups E, P+E and E+P (P>0.05; 
Table II).
ECG changes during and following gastroscopy occurred 
in 22.5% of all procedures. In group P, related transient ECG 
changes included ST segment depression (20%), transient 
atrial fibrillation (4%), sinus bradycardia (10%) and ventric-
ular premature complexes (2%). In group E, sinus bradycardia 
occurred in 12% of procedures and ST segment changes 
occurred in 6% of patients. In group P+E, the occurrence 
of bradycardia was 10%, and ST segment changes occurred 
in 8% of patients. In the E+P group, sinus bradycardia 
occurred in 8% and ST changes occurred in 6% of patients. 
The difference in the incidence of arrhythmia and ischemic 
changes between the four groups was not significant (P>0.05; 
Table II).
The occurrence of myoclonus during and following 
gastroscopy with anesthesia in group E (30%) was signifi-
cantly higher compared with groups P (2%), P+E (4%) and 
E+P (6%) (P<0.05). The occurrence of injection pain during 
and following gastroscopy in group P (64%) was significantly 
higher compared with groups E (6%), P+E (20%) and E+P (6%) 
(P<0.05). The occurrence of injection pain in group P+E was 
significant higher compared with groups E and E+P (P<0.05). 
There were no statistical differences between groups P and E 
with regards to the occurrence of body movements (P>0.05; 
Table II). One patient moved significantly enough to require 
suspension of the gastroscopy while additional propofol 
was given. The occurrence of body movements significantly 
decreased using propofol and etomidate together, regardless 
of which drug was administered first (P<0.05; Table II). Body 
movements occurred in 42 patients (21%), the majority of 
which were general body movements (97.6%). The incidence 
of PONV in group E (14%) was significantly higher compared 
with group P (8%) (P<0.05; Table II). There was no statistical 
difference in the incidence of PONV between groups P, P+E 
and E+P.
Figure 2. (A) Induction time, (B) inspection time, (C) anesthesia duration, (D) recovery time and (E) discharge time of the four study groups (n=50). Data are 
presented as the mean ± standard deviation. *P<0.05. P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by 
etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).
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Combination of propofol and etomidate increases patient 
satisfaction following a gastroscopy, as compared with using 
either agent alone. Patient evaluation of the gastroscopy is 
presented in Table III. The immediate post‑procedure ques-
tionnaire was completed by all patients. In group P, 90% of 
patients described their overall satisfaction with the anes-
thesia as ̔excellent̓ and 10% rated it ̔good̓ when asked to 
rate the degree of pain or discomfort experienced during the 
endoscopy. Meanwhile, in group E, 80% of patients described 
overall satisfaction as ̔excellent ,̓ 12% described it as ̔good̓ 
and 8% of patients described it as ̔fair .̓ In the P+E and E+P 
groups, overall satisfaction was rated as excellent in 90 and 
92% of patients, respectively, which is significantly increased 
compared with groups P and E (P>0.05; Table III).
In group P, 80% of patients reported no discomfort, 16% 
described discomfort as mild, and 4% described discomfort 
as moderate; 90% of patients rated the level of anesthesia as 
̔adequate ,̓ 8% believed that they received ̔too little ,̓ and 2% 
stated that they were given ̔too much .̓ In group E, 72% of 
patients reported no discomfort, 24% described discomfort 
as mild and 4% described discomfort as moderate; 92% 
of patients rated the level of anesthesia as ̔adequate ,̓ 6% 
believed that they received ̔too little̓ and 2% stated that they 
were given ̔too much .̓ In groups P+E and E+P, 80 and 78% 
reported no discomfort, respectively, 18 and 20% described 
discomfort as mild, respectively, and 2% in both groups 
described discomfort as moderate. All patients rated the level 
of anesthesia as ̔adequate̓ when asked to rate the level of 
anesthesia during the endoscopy following co‑administration 
of propofol and etomidate (P>0.05; Table III).
Combination of propofol and etomidate provides Although 
the survey was conducted 24 h after discharge, it was shown 
that different proportions of patients in the four groups returned 
to normal activities within 2 h of discharge. Group P patients 
required ≥4 h before resumption of activities, although the 
majority of patients did not require additional sleep following 
discharge from the endoscopy unit. There were no statistical 
differences between group P and the other three groups 
with regard to the patients' immediate and post‑procedure 
satisfaction (P>0.05; Table III). Finally, in the present study, 
a combination of propofol and etomidate provided better 
satisfaction of endoscopists (P<0.05) and anesthetists (P<0.01) 
compared with using propofol alone (Fig. 4).
Discussion
The results of the present study demonstrate that there is 
improved hemodynamic stability and minimal respiratory 
Figure 3. Mean (A) SBP, (B) DBP and (C) HR levels of the four study groups (n=50) during gastroscopy. Data are presented as the mean ± standard deviation. 
There was a significant difference between SBP in group P at T1 compared with T0 (P<0.05), and there were significant differences in SBP at T0 compared 
with SBP at T1, T2, T3, T4, T5 and T6 in group P (P<0.05). In addition, there were significant differences in SBP at T0 compared with T1, T2, T3, T4 and 
T5 in groups E, P+E and E+P (P<0.05). Furthermore, there were significant differences in SBP at T1 compared with T6 and T7 in groups E, P+E and E+P 
(P<0.05). However, there were no significant differences in HR in any groups (P>0.05). SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, 
heart rate; P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg); E+P, etomidate 
(0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).
  A   B
  C
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depression in elderly patients when propofol is used in combi-
nation with etomidate, instead of either agent used alone, for 
anesthesia during gastroscopy. Co‑administration of propofol 
and etomidate has a favorable side effect profile, allows rapid 
recovery to full activity and provides high levels of satisfaction.
Gastroscopy is a non‑traumatic invasive procedure used for 
the diagnosis of gastrointestinal pathology and for treatment for 
gastrointestinal hemorrhage, polypus and corpus alienum (3). 
Elderly patients experience specific physiological changes of 
organs and cell functions (15,16), and it is important to under-
stand how to maintain hemodynamic stability and adequate 
spontaneous respiration during gastroscopy procedures in 
such patients. Gastroscopy is frequently performed with anes-
thesia for the comfort of the patient. Elderly patients requiring 
gastroscopy frequently have cardiovascular disease and other 
co‑morbidities, which results in difficulties in safely adminis-
tering anesthesia while maintaining stable hemodynamics. The 
features of gastroscopy examination require that the anesthetic 
regimen provides rapid induction, sufficient anesthesia, hemo-
dynamic stability, quick recovery and minimal side effects.
Propofol is the most frequently used i.v. anesthetic to 
date due to its rapid recovery profile, and it has been widely 
used for anesthesia in outpatients (8,9). However, propofol 
causes marked depression on hemodynamic and respiratory 
parameters. Hypotension is a common side effect associated 
with propofol due to vasodilatation and negative inotropic 
effects (11). An induction dose of propofol results in a 25‑30% 
incidence of apnea and a 25‑40% reduction in systolic blood 
pressure (9,10). The high incidence of apnea, lasting longer than 
30 sec, exposes patients to the potential risks of brain damage, 
which is the leading cause of morbidity in anesthesia‑related 
events (17). In the present study, elderly patients induced with 
propofol experienced a 42% incidence of apnea, and 88% of 
patients experienced a significant (>30%) reduction in systolic 
blood pressure. This may be related to diminished myocardial 
contractility, decreased cardiac output, reduced ability of the 
cardiovascular system to respond to stress and preoperative 
Table II. Complications of the four study groups (n=50). 
 Group
 ----------------------------------------------------------------------------------------------------------------------------------------
Parameter P E P+E E+P
Hypotension 44 (88) 6 (12)a 6 (12)a 6 (12)a
ST segment depression 10 (20) 3 (6)a 4 (8)a 3 (6)a
Transient atrial fibrillation 2 (4) 0 (0) 0 (0) 1 (2)
Sinus bradycardia 5 (10) 6 (12) 5 (10) 4 (8)
Ventricular premature complexes 1 (2) 0 (0) 0 (0) 1 (2)
SpO2 <95% 12 (24) 2 (4)a 3 (6)a 3 (6)a
SpO2 <90% 4 (8) 0 (0)a 0 (0)a 0 (0)a
Apnea 21 (42) 7 (14)a 3 (6)a 3 (6)a
Mask assisted ventilation 4 (8) 1 (2)a 1 (2)a 1 (2)a
Body movements 13 (26) 18 (36) 5 (10)b 6 (12)b
Body movements, general 12 (24) 18 (36) 5 (10) 6 (12)
Body movements, serious 1 (2) 0 (0) 0 (0) 0 (0)
Myoclonus 1 (2) 15 (30)a 2 (4) 3 (6)
Injection pain 32 (64) 3 (6)a 10 (20)a,b 3 (6)a
PONV 4 (8) 7 (14)a 5 (10) 6 (12)
Data are n (%). aP<0.05, vs. group P, bP<0.05, vs. group E. SpO2, pulse oxygen saturation; PONV, post‑operative nausea and vomiting.
 
Figure 4. VAS score of (A) endoscopists and (B) anaesthetists of the four 
study groups (n=50). Data are presented as the mean ± standard deviation. 
*P<0.05, vs. group P; VAS, visual analogue scale; P, propofol (1.5‑2.0 mg/kg); 
E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by 
etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed 
by propofol (0.75‑1 mg/kg).
  A
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routine fasting. In contrast, etomidate is associated with 
hemodynamic stability and minimal respiratory depression, 
which are unique characteristics among rapid‑onset induction 
agents (11,18). These properties differentiate etomidate from 
other rapid‑onset induction agents, as it has a wider margin 
of safety than propofol, particularly in patients with valvular 
heart disease, myocardial ischemia and elderly patients. The 
results in the current study demonstrated that there was a 
14% incidence of apnea and a 12% incidence of hypotension 
following the use of etomidate. It is important to note that 
there is a significantly decrease in the incidence of apnea (6%), 
and a 12% incidence of hypotension, when using propofol and 
etomidate together.
Cardiopulmonary complications in elderly patients 
have been evaluated during gastroscopy. Elderly patients 
who undergo gastroscopy may be at risk of developing 
cardiopulmonary complications resulting from preexisting 
cardiovascular diseases, the sympathetic response when the 
gastroscope is inserted through the throat, and prolonged 
procedure time (5,6,19,20). In addition, elderly patients may 
be more susceptible to silent myocardial ischemia. The high 
incidence of ST segment depression in group P (20%) in the 
present study may be related to the reduction in blood pres-
sure resulting from an induction dose of propofol. Although 
1 patient developed a very high RPP (>20), and 2 patients 
experienced PRQ <1.0, it is not sufficient to conclude that 
standard‑dose propofol monotherapy exposes patients to a 
high risk of myocardial ischemia. In the current study, there 
were no differences in the incidence of transient atrial fibrilla-
tion, sinus bradycardia and ventricular premature complexes, 
Table III. Patient satisfaction surveys of four study groups (n=50). 
Question and response (n=50) P E P+E E+P
How much discomfort or    
pain did you feel?    
  None  40 (80) 36 (72) 40 (80) 39 (78)
  Mild  8 (16) 12 (24) 9 (18) 10 (20)
  Moderate  2 (4) 2 (4) 1 (2) 1 (2)
  Severe  0 0 0 0
Rate the level of sedation received    
during the endoscopic exam    
  Adequate  45 (90) 46 (92) 50 (100) 50 (100)
  Too little 4 (8) 3 (6) 0 0
  Too much 1 (2) 1 (2) 0 0
Rate your overall satisfaction with    
the endoscopic sedation    
  Excellent 45 (90) 40 (80) 45 (90) 46 (92)
  Good 5 (10) 6 (12) 4 (8) 3 (6)
  Fair 0 4 (8) 1 (2) 1 (2)
  Poor 0 0 0 0
Did you require additional sleep during    
the day after your procedure?    
  Yes 14 (28) 16 (32) 12 (24) 11 (22)
  No 36 (72) 34 (68) 38 (76) 39 (78)
How much sleep did you require?    
  None 36 (72) 34 (68) 38 (76) 39 (78)
  <2 h  9 (18)  11 (22) 9 (18) 8 (18)
  2-4 h 4 (8) 4 (8) 3 (8) 3 (8)
  4‑6 h 1 (2) 1 (2) 0 (0) 0 (0)
When did you resume your normal daily    
activities?    
  <2 h 35 (70) 36 (72) 40 (80) 41 (82)
  2‑4 h 9 (18) 8 (16) 5 (10) 4 (8)
  4‑6 h 3 (6) 3 (6) 2 (4) 2 (4)
  >6 h 3 (6) 2 (4) 3 (6) 3 (6)
Data are n (%). In the P+E and E+P groups, overall satisfaction was rated as excellent in 90 and 92% of patients, respectively; this is signifi-
cantly higher compared with groups P and E (P>0.05).
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which indicate that temporary short periods of fluctuations 
in blood pressure have little effect on the cardiac conduction 
system. Propofol is a potent hypnotic agent that can cause 
life‑threatening side effects, including the loss of protective 
airway reflexes and respiratory depression (17,21). In the 
present study, it was observed that 8% of elderly patients in 
group P required short‑term positive pressure ventilation, 
while 2% of elderly patients in the other three groups required 
this intervention. This result demonstrates that etomidate has 
unique characteristics which allow it to be used alone or in 
combination with propofol for anesthesia. In addition, the 
results show that a combination of etomidate and propofol can 
result in favorable hemodynamic stability and preserve spon-
taneous respirations during anesthesia for gastroscopy.
Etomidate has rarely been used in outpatient opera-
tions and during examination due to side effects, such as 
myoclonus and PONV. Etomidate has been observed to be 
associated with a high (30‑40%) incidence of PONV, and the 
incidence of myoclonus following etomidate use is highly 
variable (0‑70%) (22,23), which is higher than propofol (22). 
In the present study, the incidence of myoclonus, PONV and 
injection pain when etomidate combined with propofol was 
used and injected in different sequences, was investigated. 
The results demonstrate that the incidences of PONV and 
myoclonus in group E (14 and 30%, respectively) are higher 
compared with group P (8 and 2%), and are reduced by 
combined use with propofol (10 and 12% PONV in groups 
P+E and E+P, respectively; 4 and 6% myoclonus in groups 
P+E and E+P, respectively). In addition, the current study 
observed a decreased incidence of injection pain following 
the combined use of propofol and etomidate. All of the results 
demonstrate that the combined use of propofol and etomidate 
results in reducedside effects, including myoclonus, injection 
pain and PONV, in elderly patients undergoing gastroscopy. 
Furthermore, the present study demonstrated that the combined 
use of propofol and etomidate for endoscopic anesthesia, alone 
or in combination, results in high levels of patient satisfaction.
In the present study, it was anticipated that a short recovery 
time would be accompanied by a rapid recovery to full 
activity. In telephone surveys conducted 24 h after discharge 
in the current study, it was reported that 72% of patients did 
not require additional sleep following discharge, and that 70% 
resumed normal activities within 2 h of departure from the 
endoscopy unit when propofol monotherapy was used, which 
is in agreement with the other results (8). The novel finding 
of the present study revealed that 76 and 78% of patients in 
groups P+E and E+P, respectively, did not require additional 
sleep following discharge, and that 80 and 82% of patients 
in groups P+E and E+P, respectively, resumed normal activi-
ties within 2 h of departure from the endoscopy unit. This 
demonstrates that the combined use of propofol and etomidate 
can result in a rapid return to full activity for elderly patients 
following gastroscopy.
The present study is subject to a number of limitations. 
Firstly, the current study is not a multi‑center study; further 
research should be conducted at multiple sites. Although the 
study supports the hypothesis that the combined use of etomidate 
and propofol reduces the side effects of etomidate and propofol 
with minimal effects on safety and recovery, a larger trial that 
is sufficient to detect differences is needed to confirm these 
findings before a change in clinical practice is recommended. 
Secondly, although plasma corticosteroid concentrations 
were not recorded in the current study, a number of studies 
have demonstrated that the induction dose of etomidate can 
decrease plasma corticosteroid concentrations, and that this 
can be sustained for 6‑8 h, leading to adrenocortical dysfunc-
tion (24‑26). Thirdly, only the short‑term hemodynamic effects 
on elderly patients were investigated. Although no significant 
difference was identified in the mortality and hospitalization 
among patients who received propofol or etomidate, it can not 
determine whether there is any effect on mortality or other 
aspects of clinical outcome.
In conclusion, the present study demonstrates that anes-
thesia for gastroscopy in elderly patients can be safely and 
effectively accomplished when propofol combined with etomi-
date is used. It is understood that these anesthetic regimens 
have unique characteristics, including improved hemodynamic 
stability, minimal respiratory depression, reduced side effects, 
a rapid return to full activity and high levels of satisfaction.
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